Abeona Therapeutics Inc (ABEO.OQ)
13 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2015||Executive Chairman of the Board|
|45||2015||President, Chief Executive Officer, Director|
|54||2017||Chief Operating Officer|
|64||2016||Senior Vice President - Research and Development|
|2017||Senior Vice President - Plasma|
- BRIEF-Abeona Q3 loss per share $0.13
- BRIEF-Abeona Therapeutics prices offering of five million shares at $16 per share
- BRIEF-Abeona Therapeutics announces public offering of common stock
- BRIEF-Abeona Therapeutics to receive $13.85 mln of grants for development of Sanfilippo gene therapy programs
- BRIEF-Abeona Therapeutics enrolls first two patients in phase 1/2 clinical trial in MPS IIIA